Lifetech Scientific (01302) dropped more than 14% intraday. As of press time, it was down 11.45% at HK$1.47, with turnover of HK$225 million.
On the news front, on November 6, Zylox-Tonbridge announced it had joined with Defu Capital to establish a shareholding platform to subscribe for 926 million newly issued shares of Lifetech Scientific at HK$1.60 per share, for a total of approximately HK$1.482 billion. After the transaction is completed, the platform will hold approximately 16.7% of Lifetech Scientific's enlarged share capital, becoming its largest single shareholder. Zylox-Tonbridge's management will go to Lifetech Scientific to serve as CEO and CFO.
It is worth noting that in May this year, Lifetech Scientific announced plans to acquire approximately 96.46% equity interest in Beijing Huayi Shengjie for approximately RMB 1.873 billion, with the consideration to be paid entirely in convertible bonds. The counterparty is ultimately controlled by Hillhouse Capital after look-through. If all the bonds are converted into shares, Hillhouse would hold approximately 15.66% of Lifetech's enlarged share capital and was expected to become the largest shareholder. On July 20, Lifetech Scientific announced it would no longer proceed with the transaction; on November 5, the two parties formally signed a termination agreement.
Comments